{
  "id": 51472,
  "title": "Tumor-specific CD4 T cells cooperate with myeloid cells to remodel the pancreatic tumor microenvironment and enable effective immunotherapy",
  "url": "https://urgent.news/2026/08/01/tumor-specific-cd4-t-cells-cooperate-with-myeloid-cells-to-remodel",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-01T00:00:00.000Z",
  "source": {
    "name": "bioRxiv",
    "slug": "biorxiv",
    "url": "https://www.biorxiv.org/content/10.64898/2026.07.28.741325v1?rss=1"
  },
  "original_language": "en",
  "account": "Pancreatic ductal adenocarcinoma patients who receive immunotherapy with MHC-II-restricted tumor epitopes show superior protection compared to those with immunodominant MHC-I epitopes. This has led to the development of MHC-II affinity-enhanced tetramers to track tumor-specific CD4 T cells. As the tumors progress, tumor-specific CD4 T cells decline and acquire regulatory features. Agonistic anti-CD40 increases Th1 cell clonal expansion and temporarily decreases Tregs, while anti-PD-L1 promotes Tfh clonal expansion and tumor presence, preventing Treg rebound after anti-CD40 treatment. Treatment with anti-CD40 promotes intratumoral Stat1+ macrophages, tertiary lymphoid structures, and immune triads in tumors. The presence of MHC-II on myeloid cells, but not B cells, is essential for immunotherapy-induced tertiary lymphoid structure formation and antitumor effects. The IL-15 complex enhances immunotherapy-induced Th1 effectors without promoting Tregs. Human immunotherapy transcriptomics reveals that effective response in patients is characterized by conserved Th1 programming and Treg destabilization. In conclusion, tumor-specific CD4 T cells play a central role in the effectiveness of immunotherapy in solid tumors.",
  "summary": "We interrogate antigen-specific CD4 T cells during immunotherapy in pancreatic ductal adenocarcinoma. Vaccination with MHC-II-restricted tumor epitopes impart superior protection compared to an immunodominant MHC-I epitope, prompting development of MHC-II affinity-enhanced tetramers to track tumor-specific CD4 T cells. As tumors progress, tumor-specific CD4 T cells decline, and remaining cells…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}